Dna molecules encoding l-glutamate-gated chloride channels from rhipicephalus sanguineus
CA 2405268 C · Owner: Boehringer Ingelheim Animal Health Usa Inc. · Inventors: Warmke, Jeffrey W.; Yang, Youfeng; Hamelin, Michel J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode Rhipicephalus sanguineus glutamate gated chloride channels. The present invention also relates to recombinant vectors and recombinant hosts which contain a DNA fragment encoding R. sanguineus glutamate gated chloride channels, substantially purified forms of associatedR. sanguineus glutamate gated chloride channels and recombinant membrane fractions comprising these proteins associated mutant proteins, and , methods associated with identifying compounds which modulate associated Rhipicephalus sanguineus glutamate gated chloride channels which will be , useful as insecticides.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 28, 2001 and granted September 25, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 28, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 28, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.